Elicio Therapeutics Azioni (NASDAQ: ELTX)

Ultime notizie per Elicio Therapeutics (NASDAQ:ELTX) Azioni

Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Elicio Therapeutics Inc

JMP Securities analyst Joe Goodwin maintains Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) with a Market Outperform and raises the price target from $200 to $231.

News

Price Target

Analyst Ratings

GWRE

JMP Securities Maintains Market Outperform on Guidewire Software, Raises Price Target to $231

Trading Ideas

QMCO

Quantum Corp Shares Halted On Circuit Breaker To The Upside, Stock Now Up 186.9%

Citigroup analyst Keith Horowitz maintains Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) with a Neutral and raises the price target from $47 to $51.

Citigroup Maintains Neutral on Truist Finl, Raises Price Target to $51

Quantum Corp Shares Resume Trading

The tech job market is in a tough spot right now. People like Jon Bach, a former director at eBay, are feeling the squeeze. Bach worked at eBay for 13 years, but after getting laid off in January, his job search hasn't gone as planned.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>
&#8220;I don&#8217;t know what&#8217;s going on,&#8221; Bach said to Business Insider in a recent interview. &#8220;I&#8217;ve been doing this for a minute and I&#8217;ve proven my value. And then you apply to one place, two places, 10 places, 50 places, 135 places. And you go, &#8216;Am I the guy I think I am?'&#8221; Despite applying to 135 jobs, he's received only two callbacks and no offers.
It's not just Bach. Many white-collar professionals are struggling. The broader labor market looks fine on the surface. But for six-figure earners, <a href="https://www.benzinga.com/news/24/09/40724455/peter-schiff-says-illusion-of-a-strong-labor-market-fading-faster-than-kamala-harris-post-convention">it's a whole different story. </a>Data shows hiring for high-paying jobs has tanked. <a href="https://economicgraph.linkedin.com/workforce-data">New data from LinkedIn</a> highlights just how bad it is. IT hiring is down 27%. Quality assurance roles have dropped 32%. Product management is down 23% and engineering – once considered recession-proof – has fallen 26%.
Even in Bach's field, program and project management, hiring has slumped 25%. These numbers are shocking for a sector like tech. The sector once treated coders and engineers like "rare minerals." In Silicon Valley, cutting back on these roles was almost unthinkable, no matter how the economy was doing.
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a>
What's going on? There are a few reasons for this slowdown. During the pandemic, tech companies went on a hiring spree to keep up with demand. Now, they're cutting back. Some companies turned to mass layoffs, while others opted for hiring freezes and letting natural attrition shrink their teams.
Jenny Diani, a senior recruiter at Autodesk, sees it firsthand. &#8220;Candidates are being much more careful,&#8221; she told BI. Voluntary turnover in tech is way down, so companies don't need to hire as much.
In addition, AI tools like ChatGPT are making workers more efficient. Google has said that AI generates over 25% of its new code. This means companies can slow hiring without feeling the pinch.
Trending: This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a>
<a href="https://www.benzinga.com/real-estate/24/07/39748005/housing-market-eyes-relief-as-weak-job-numbers-and-4-1-unemployment-hint-at-september-rate-cut">The slowdown </a>is frustrating for job seekers. Santiago Rodriguez, a data scientist, has applied to 669 positions. He even built a dashboard to track his applications. &#8220;There's so much angst,&#8221; said Jon Stross, cofounder of Greenhouse, a hiring software company, to BI.
The number of applicants per job is also skyrocketing. Greenhouse reported an average of 222 applications per job opening in early 2024, up from 77 in late 2021. With so many resumes flooding in, hiring managers are overwhelmed.
There's a glimmer of hope, though. Some experts believe the worst of what BI calls the "white-collar recession" might be over. Art Zeile, CEO of Dice, told BI that tech job openings have climbed from 144,000 at the end of last year to 223,000. While it's still below pre-pandemic levels, it's progress.
Bach is optimistic. &#8220;I think a lot of people like me are eager to get back to work,&#8221; he said. &#8220;If you take a risk on me, I'll show you that I'm worth it.&#8221;
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

Six-Figure Job Market Faces 'White-Collar Recession' As LinkedIn Reports 26% Drop In Engineering Roles

WIIM

KULR

KULR Technology Group shares are trading higher after the company announced it won a contract by the U.S. Navy to advance its Internal Short Circuit technology to activate at higher temperatures. Also, the CEO and Co-Founder, Michael Mo, on X posted that the company is building the next digital energy management platform.

Summit Materials, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) shares are trading higher on Monday. The company inked a definitive deal to be acquired by privately owned family business Quikrete Holdings for $52.50 per share in cash, valuing the transaction at <a href="https://www.benzinga.com/pressreleases/24/11/n42159941/summit-materials-enters-into-definitive-agreement-to-be-acquired-by-quikrete-for-52-50-per-share-i" target="_blank" rel="noreferrer noopener">approximately $11.5 billion, including debt</a>.
The deal price&nbsp;represents a 36% premium to Summit&#8217;s 90-day volume-weighted average price and a 29% premium to its unaffected share price. In October, Summit Materials disclosed receiving<a target="_blank" href="https://www.benzinga.com//node/41535519" rel="noreferrer noopener"> a non-binding acquisition proposal.</a>
The deal has been unanimously approved by both Summit and Quikrete&#8217;s Boards of Directors.
The transaction will combine Summit&#8217;s aggregates, cement, and ready-mix concrete businesses with Quikrete&#8217;s concrete and cement-based products, creating a vertically integrated North American construction materials provider with strong customer relationships and iconic products.
The transaction is expected to close in the first half of 2025, pending Summit shareholder approval, regulatory clearances, and other customary closing conditions.
Once completed, Summit will become a privately held subsidiary of Quikrete, and its common stock will no longer be traded on the NYSE.
Anne Noonan, Summit Materials President and Chief Executive Officer, said, &#8220;This combination, and the value it creates, is a testament to our stellar strategic and financial performance, agile operational and commercial execution, and to the strength and talent of our entire team who have delivered a 34.6% annualized return since we began to develop our Elevate strategy on&nbsp;September 1, 2020.&#8221;
Will Magill, Chief Executive Officer of Quikrete, stated, &#8220;This acquisition represents a significant milestone in our journey to expand our capabilities and geographic presence. Summit is a recognized leader with a highly complementary portfolio of trusted aggregate, cement and ready-mix solutions.&#8221;
The company&#8217;s stock has gained over 12% in the past month. Investors can gain exposure to the stock via&nbsp;Professionally Managed Portfolios Congress SMid Growth ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSMD#NYSE">CSMD</a>) and Invesco Dorsey Wright Basic Materials Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYZ#NASDAQ">PYZ</a>).
Price Action: SUM shares are trading lower by 1.72% at $50.77 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42162996" target="_blank" rel="noreferrer noopener">Vertical Aerospace Soars: $50 Million Funding Boost And Debt Conversion Propel eVTOL Maker Forward</a></li>
</ul>
Photo by haneen-krimly for Unsplash.

Equities

CSMD

PowerShares Dynamic Basic Materials Sector Portfolio

Summit Materials Scooped Up: Quikrete Strikes $11.5 Billion Deal To Cement Industry Presence

Citigroup analyst Keith Horowitz maintains Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) with a Neutral and raises the price target from $75 to $82.

Citigroup Maintains Neutral on Bank of New York Mellon, Raises Price Target to $82

Quantum Corp Shares Halted On Circuit Breaker To The Upside, Stock Now Up 169.4%

Biotech

General

INCY

Incyte To Present Late-Breaking Tafasitamab Data In Follicular Lymphoma At ASH 2024 Alongside 20 Oncology Portfolio Updates, Including Phase 3 inMIND Results And Virtual Analyst Event On December 12

Citigroup analyst Tyler Radke maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Buy and raises the price target from $136 to $150.

ESTC

Citigroup Maintains Buy on Elastic, Raises Price Target to $150

TD Cowen analyst Charles Ryhee maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Buy and raises the price target from $73 to $80.

TD Cowen Maintains Buy on CVS Health, Raises Price Target to $80

Quantum Corp Shares Resume Trade

The Benzinga Future of Digital Assets event highlighted the importance of breaking down barriers in investing, with leaders exploring ways to expand financial participation. Andrew McCormick, head of eToro US, shared his vision for a more inclusive financial future and a promising outlook for cryptocurrency and technology markets.
<h3 class="wp-block-heading">Making Investing Accessible to Everyone</h3>
McCormick argued that there is a pressing need to increase the number of Americans participating in the stock market. Referencing a recent federal report, he noted that only 58% of the population currently holds investments.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42159139/microstrategy-shares-rise-in-monday-pre-market-as-michael-saylor-reveals-mstr-generating-500m-daily-amid-bitcoins-surge">MicroStrategy Shares Rise In Monday Pre-Market As Michael Saylor Reveals MSTR Generating $500M Daily Amid Bitcoin&#8217;s Surge</a>
"We want to see more people investing. It's such a great way to break down barriers, give people additional hope and opportunity," he said, emphasizing the role of companies like eToro in encouraging broader engagement.
<h3 class="wp-block-heading">A Promising Year Ahead for Bitcoin and Technology</h3>
Looking forward, McCormick expressed optimism for Bitcoin's performance in the coming year and the role of new technologies in shaping financial systems. "I think it's going to be a huge year for Bitcoin, specifically," he explained. He also highlighted the transformative potential of artificial intelligence, predicting it will dramatically impact everyday life and investment strategies.
McCormick offered a straightforward approach to those hesitant to begin investing. "Don't stress about trying to time the market perfectly. Just get started. Take small steps and learn as you go," he advised. His message underscores the importance of taking initial steps, no matter how small, to build financial confidence over time.
<h3 class="wp-block-heading">Building Momentum Through Collaboration</h3>
As leaders at the event discussed the future of digital assets, McCormick highlighted the value of collaboration in fostering a more inclusive investment environment. His remarks aligned with the conference&#8217;s focus on innovative ideas and shared strategies to make investing accessible to a wider audience.
The insights shared at the event reflect a broader movement to empower individuals and reshape how people approach financial markets.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42163156/why-bitcoins-rally-is-stalling-below-100000">Why Bitcoin Is Stalling Below $100,000</a></li>
</ul>
Photo by SvetlanaParnikova on Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

'Don't Stress About Timing The Market': Advice For New Investors

TD Cowen analyst John Kernan maintains Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) with a Buy and raises the price target from $288 to $334.

BURL

TD Cowen Maintains Buy on Burlington Stores, Raises Price Target to $334

With India positioning itself as a significant player in the global semiconductor landscape, Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) <a href="https://www.benzinga.com/topic/india">is doubling its investments</a>. 
The chipmaking giant views India as a burgeoning market and an essential development hub for innovation and technology growth.
Speaking <a href="https://www.cnbctv18.com/business/amd-ceo-lisa-su-india-essential-development-hub-19513318.htm" target="_blank" rel="noreferrer noopener">to</a> CNBC, AMD CEO Lisa Su highlighted India&#8217;s strategic importance, calling it integral to the company&#8217;s global operations. The Bengaluru design center, AMD&#8217;s largest R&amp;D facility outside the U.S., employs over 8,000 people. It also plays a crucial role in hardware, software, and systems development.
AMD has pledged $400 million in investments in India through 2028. The goal is to bolster its infrastructure and foster a comprehensive semiconductor ecosystem.
Su <a href="https://economictimes.indiatimes.com/tech/technology/every-amd-product-goes-via-india-team-chair-ceo-lisa-su/articleshow/115540041.cms?from=mdr" target="_blank" rel="noreferrer noopener">told</a> the Economic Times that AMD is collaborating with the Indian government to develop two supercomputers focused on weather forecasting. She described these projects as examples of the suitable investments being made in the country. 
Additionally, Su highlighted the potential of artificial intelligence (AI) as the most transformative technology in five decades, with AMD&#8217;s products aiming to make AI more efficient and accessible over time.
Su emphasized that India plays a pivotal role in AMD&#8217;s global portfolio. Every product line passes through the country&#8217;s design center. These initiatives align with India&#8217;s ambitions to become a leader in semiconductor manufacturing and artificial intelligence.
Establishing such ecosystems requires time, Su says. She&#8217;s also optimistic about India&#8217;s progress, pointing to its success in attracting global investments and developing critical infrastructure.
AMD plans to <a target="_blank" href="https://www.benzinga.com/24/11/41961230/amd-plans-to-cut-4-of-workforce-amid-strategic-shift-toward-ai-chip-development-to-rival-jensen-huang-led-nvidias-dominance-report" rel="noreferrer noopener">cut around 1,000 jobs</a>, accounting for 4% of its global workforce, as part of its resource realignment strategy.
The chip designer aims to sharpen its focus on competing with Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
The chipmaker has been heavily investing in developing AI chips, which are highly sought after by significant hyperscalers such as Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>). These high-performance chips come with a substantial price tag and are crucial in expanding AMD&#8217;s presence in the AI market.
Price Action: AMD stock is up 1.85% at $140.91 premarket at last check Monday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42164927/cassava-sciences-controversial-alzheimers-drug-fails-to-hit-primary-goal-in-pivotal-study-halts-late-stage-studies">Cassava Sciences Alzheimer&#8217;s Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies</a></li>
</ul>
Image: Shutterstock

Asia

Government

Tech

Media

MSFT

NVDA

AMD Boosts India Presence With $400 Million Investment, Supercomputers For Weather Forecasting

Quantum Corp Shares Halted On Circuit Breaker To The Upside, Stock Now Up 122.1%

Anglo American (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AAUKF#OTC">AAUKF</a>) has agreed to sell its Australian steelmaking coal portfolio to Peabody Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) for up to $3.8 billion. The sale marks another step toward future-facing commodities, following the $1.1 billion sale of its stake in the Jellinbah Group <a href="https://www.benzinga.com/news/large-cap/24/11/41739206/anglo-american-offloads-1-1-billion-coal-stake-proceeds-with-restructuring">earlier this month</a>.
&#8220;We're pleased to acquire these world-class assets from Anglo American, a company that shares our strong values of safety, sustainability, and social license to operate,&#8221; <a href="https://www.angloamerican.com/media/press-releases/2024/25-11-2024">said</a> Peabody CEO Jim Grech. &#8220;We look forward to integrating these assets, teaming up with their highly skilled workforce, and aligning with our new mine joint venture partners to create long-term value.&#8221;
This coal portfolio includes an 88% stake in the Moranbah North JV, a 70% interest in the Capcoal JV, and several other major interests, such as the Dawson and Roper Creek JVs. These assets are critical producers of metallurgical coal, essential for steelmaking, and should be meaningful contributors to Peabody&#8217;s operations.
Per the deal's terms, Anglo American will receive an upfront cash payment of $2.05 billion, deferred cash payments totaling $725 million, a price-linked earnout of up to $550 million, and $450 million contingent on the reopening of the Grosvenor mine. The deal will close by Q3 2025, pending regulatory approvals.
Also Read: <a href="https://www.benzinga.com/news/global/24/11/42156160/palantir-price-target-raised-to-75-by-dan-ives-amid-288-ytd-surge-analyst-calls-2025-a-primetime-year-for-ai">Palantir Price Target Raised To $75 By Dan Ives Amid 288% YTD Surge: Analyst Calls 2025 A &#8216;Primetime&#8217; Year For AI</a>
&#8220;The sale of our steelmaking coal business is another important step toward delivering the strategy we set out in May to create a world-class copper, premium iron ore, and crop nutrients business. We're focused on streamlining costs, simplifying our portfolio, and unlocking market value,&#8221; said Anglo American CEO Duncan Wanblad.
The company has set a target of $1 billion in cost savings by 2025 and expects an additional $800 million in recurring pre-tax benefits. The broader restructuring plan includes divesting from coal, platinum, nickel, and diamonds. The demerger of Anglo American Platinum (Amplats) is expected by mid-2025, and the nickel business sale is progressing with strong interest.
The crown jewel of Anglo American&#8217;s portfolio, De Beers, remains on books. Weaker Chinese diamond demand and an influx of synthetics have created persisting weakness, making asset sales unattractive.
Earlier this year, Anglo American embarked on a major restructuring to fend off a <a href="https://www.benzinga.com/news/large-cap/24/05/39068033/time-runs-out-for-bhp-deal-49-billion-acquisition-of-anglo-american-proves-too-complex-to-solve">takeover bid from BHP</a>. To position itself for long-term growth, the company is focusing on high-margin, future-facing minerals like copper, quality iron ore, and crop nutrients.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42135153/mexicos-increased-mining-royalties-could-deter-7-billion-in-foreign-investments">Mexico&#8217;s Increased Mining Royalties Could Deter $7 Billion In Foreign Investments</a></li>
</ul>

Commodities

AAUKF

Anglo American Sells Coal Portfolio For $3.8 Billion

<a href="https://www.globenewswire.com/Tracker?data=WVHca8aAB5_CJSALiU4s_ywNZ4O0DYj6z-1DZbut8kG5sM32VITm6AVcm7fHueyWufVk-8cIr_O4JymiEBg1RZfrmDsEsit_V1Wgj3ShdKhr3RtHE6rkrhd4yTfZqPEL">Alignment Health Plan</a>, an award-winning Medicare Advantage (MA) plan from Alignment Health, today announced that members enrolled in its HMO plans in Maricopa County now have access to over 4,500 primary care providers, specialists and hospitals, including more than a dozen Banner Health hospitals, through its partnership with <a href="https://www.globenewswire.com/Tracker?data=tjKYqJ9X9SAtefAByAutg02SeZugWiyfjGjvd2HwdtQXW5WZNYREB_aGReugBw4uRrsGh95v49oxIWMQlayL0LoKDV2CFkT944DuLX9363z8DUUJyyAjg4f3o44iJaf9rdrU5vH5OQziyAdXw0OFkaDfzOpnFmQl1yeI8dp8k9o=">Arizona Priority Care, an affiliate of Heritage Provider Network</a>.
Arizona Priority Care first entered into an <a href="https://www.globenewswire.com/Tracker?data=d4CjNyxKb8IVRvJ2aBsxdr4RCUIBV-_SBcKCLCCb5_p1uSKDfYRmfgnXNAykP8HyAQ9kKgolft6gyKE_lYOicKzSkVU3aQBsCM4W0iouHYe4BopdNh3TGDSSFlCmYg4bzAOBZoQRNIQmIYp71_EFAHrCjFcgUEUexhsG2xQVUy5uE3qIaXrzW8k_TvnBy3vQreoi89cJDbDK7eyLr1SOejP2VuUkEnSdhofwY6YPuwE=">agreement</a> with Alignment when the MA plan debuted in the state in 2022. Through this relationship, Alignment Health Plan members will now have expanded access to Arizona Priority Care's network of providers and hospitals that serve Maricopa County.

ALHC

Alignment Health Plan Expands Access To Care In Arizona Through Enhanced Agreement With Arizona Priority Care

Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-26. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Ambarella will report an earnings per share (EPS) of $0.04.
The market awaits Ambarella's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.06, which was followed by a 10.63% increase in the share price the next day.
Here's a look at Ambarella's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.19</td>
<td>-0.31</td>
<td>-0.33</td>
<td>-0.39</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.13</td>
<td>-0.26</td>
<td>-0.24</td>
<td>-0.28</td>
</tr>
<tr>
<td>Price Change %</td>
<td>11.0%</td>
<td>21.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732546938_0.png" alt="eps graph" />
<h3>Market Performance of Ambarella's Stock</h3>
Shares of Ambarella were trading at $63.62 as of November 22. Over the last 52-week period, shares are up 19.48%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about Ambarella</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Ambarella.
The consensus rating for Ambarella is Buy, derived from 9 analyst ratings. An average one-year price target of $75.0 implies a potential 17.89% upside.
<h3>Analyzing Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Diodes, Synaptics and Silicon Laboratories, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Diodes is maintaining an Buy status according to analysts, with an average 1-year price target of $68.5, indicating a potential 7.67% upside.</li>
<li>Analysts currently favor an Buy trajectory for Synaptics, with an average 1-year price target of $101.75, suggesting a potential 59.93% upside.</li>
<li>The consensus outlook from analysts is an Neutral trajectory for Silicon Laboratories, with an average 1-year price target of $111.4, indicating a potential 75.1% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Diodes, Synaptics and Silicon Laboratories, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ambarella</td>
<td>Buy</td>
<td>2.58%</td>
<td>$38.74M</td>
<td>-6.33%</td>
</tr>
<tr>
<td>Diodes</td>
<td>Buy</td>
<td>-13.49%</td>
<td>$118.01M</td>
<td>0.77%</td>
</tr>
<tr>
<td>Synaptics</td>
<td>Buy</td>
<td>8.41%</td>
<td>$120.90M</td>
<td>-1.57%</td>
</tr>
<tr>
<td>Silicon Laboratories</td>
<td>Neutral</td>
<td>-18.34%</td>
<td>$90.31M</td>
<td>-2.62%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Ambarella is positioned at the top for Revenue Growth with 2.58%. It is at the bottom for Gross Profit with $38.74M. Ambarella is at the bottom for Return on Equity with -6.33%.
<h3>All You Need to Know About Ambarella</h3>
Ambarella Inc is a developer of semiconductor processing solutions for high-definition video capture, sharing, and display. The firm's solutions are sold to original design manufacturers and original equipment manufacturers to be designed for use in infrastructure broadcast encoders, wearable device cameras, automotive cameras, and security cameras. Ambarella's system-on-a-chip designs, based on its proprietary technology platform, are highly configurable to applications in various end markets. Geographical presence in Taiwan, Asia Pacific, Europe, North America, and the United States. The firm derives the majority of its revenue from Taiwan.
<h3>Ambarella's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Ambarella displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately 2.58%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Ambarella's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -54.75%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Ambarella's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -6.33%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ambarella's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.41%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Ambarella's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/AMBA/earnings">To track all earnings releases for Ambarella visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

AMBA

A Look Ahead: Ambarella's Earnings Forecast

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Elicio Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/eltx-stock-quote/">ELTX</a>) just reported results for the second quarter of 2024.<ul><li>Elicio Therapeutics reported earnings per share of -64 cents. This was above the analyst estimate for EPS of -96 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/eltx-stock-earnings-elicio-therapeutics-for-q2-of-2024/">ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024

Elicio Therapeutics GAAP EPS of -$0.64

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Elicio Therapeutics (ELTX – Research Report) and keeping the price target at $...

Elicio Therapeutics: A Strong Buy on Improved Financials and Promising Clinical Trials

An announcement from Elicio Therapeutics (ELTX) is now available. Brian Piekos has announced his resignation as CFO and Treasurer of Elicio Therape...

Elicio Therapeutics CFO Brian Piekos Resigns Amicably

An announcement from Elicio Therapeutics ( ($ELTX) ) is now available. Elicio Therapeutics has appointed Robert Connelly as its Principal Accountin...

Elicio Therapeutics Appoints Robert Connelly as Financial Officer

JonesResearch analyst Soumit Roy initiated coverage of Elicio Therapeutics (ELTX) with a Buy rating and $9 price target Elicio's off-the-shelf canc...

Elicio Therapeutics initiated with a Buy at JonesResearch

Elicio Therapeutics (ELTX) presented updated preliminary results from the ongoing AMPLIFY-7P Phase 1 clinical trial of ELI-002, an Amphiphile cance...

Elicio Therapeutics presents updated preliminary results from AMPLIFY-7P

JonesTrading analyst Soumit Roy maintained a Buy rating on Elicio Therapeutics (ELTX – Research Report) today. The company's shares opened today at...

Elicio Therapeutics (ELTX) Receives a Buy from JonesTrading

Elicio Therapeutics GAAP EPS of -$1.39

ELTX

Screenshot 2024-06-07 at 5.22.00 PM

Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors

Screenshot 2024-04-10 at 5.39.01 PM

Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry

Screenshot 2024-04-04 at 5.26.54 PM

Unlocking The Power Of Immunotherapy: Elicio Therapeutics&#39; (NASDAQ: ELTX) Novel AMP Platform

Financing

Press Releases

Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering

Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Health Care

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ("SITC") 2024 Annual Meeting

Comments

Elicio Therapeutics

Notizie

Ultime notizie per Elicio Therapeutics (NASDAQ:ELTX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO